Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
|
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Unveiling therapeutic targets for esophageal cancer: A comprehensive review.
Curr. Oncol. 30, 9542-9568 (2023)
Esophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted with drugs like trastuzumab and cetuximab, and immunotherapy drugs like pembrolizumab and nivolumab show promise by targeting immune checkpoint proteins. Epigenetic modifications offer new avenues for targeted therapy. Treatment selection depends on factors like stage, tumor location, and patient health, with post-operative and rehabilitation care being essential. Early diagnosis, appropriate treatment, and supportive care are key to improving outcomes. Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Esophageal Cancer ; Molecular Markers ; Multidisciplinary Approach ; Prognosis ; Targeted Therapy; Quality-of-life; Endoscopic Submucosal Dissection; Minimally Invasive Mckeown; Endothelial Growth-factor; Squamous-cell Carcinoma; Term-follow-up; Mucosal Resection; Esophagogastric Junction; Barretts-esophagus; Management
ISSN (print) / ISBN
1198-0052
e-ISSN
1718-7729
Journal
Current Oncology
Quellenangaben
Volume: 30,
Issue: 11,
Pages: 9542-9568
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Lung Health and Immunity (LHI)